Genfit SA (GNFT) has released an update.
GENFIT SA, a biopharmaceutical company focusing on severe liver diseases, announced a partnership with the European Foundation for the Study of Chronic Liver Failure to enhance research on Acute on-Chronic Liver Failure (ACLF). At the EASL Congress™ 2024, GENFIT will present new research data and engage in discussions on patient-centered healthcare. The company’s diverse R&D portfolio, including five assets targeting ACLF, demonstrates its commitment to addressing this syndrome with a high mortality rate and growing incidence.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
